Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual antiplatelet therapy (aspirin plus ticagrelor or clopidogrel) in patients who underwent coronary angioplasty. Patrick Serruys presented this work (which was simultaneously published in The Lancet) at the European Society of Cardiology (ESC) Congress 2018 and explained that, given…
Report on Cardiovascular Death in Mexico Within the SOLACI-SOCIME 2018 Congress
How can you know if you are having an infarction? What is the rate of cardiovascular death in Mexico? What are the possible solutions to this problem? José Luis Leiva Pons, SOLACI president, and Jorge Cortés Lawrenz, SOLACI-SOCIME 2018 Congress chair, analyzed the situation of cardiovascular health in Mexico during the SOLACI-SOCIME 2018 Congress that…
ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation
Courtesy of Dr. Carlos Fava. In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ventricular geometry and function. At present, prognosis is based on ventricular function and the regular course of action is optimal medical treatment. Even though some studies have shown edge-to-edge percutaneous repair…
ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention
Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular disease. However, something that a short time ago seemed obvious could not be proved by randomizing 12,000 patients. The ARRIVE trial, presented at the European Society of Cardiology (ESC) Congress 2018 and simultaneously published in The Lancet, joins the…
ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction
This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction in stable patients and offer no survival benefit to patients with stable ischemic heart disease who have not experienced a myocardial infarction. This analysis represents 5 years of follow-up in a large, multinational registry and also shows a lack…
ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis
The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow of doubt over the indication of aspirin for primary prevention in diabetic patients. According to the ASCEND trial, presented at the European Society of Cardiology (ESC) 2018 Congress and simultaneously published in NEJM, aspirin reduces cardiovascular events as…
SOLACI-SOCIME 2018 | Primary angioplasty and cardiogenic shock
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Cindy Grines, entitled “Primary angioplasty and cardiogenic shock”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | Real world supported unprotected LM PCI with impella device
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Cindy Grines, entitled “Real world supported unprotected LM PCI with impella device”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | Bio Active Stents
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Pasi Karjalainen, entitled “Bio Active Stents”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI-SOCIME 2018 | Multivascular PCI
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Jorge Saucedo, entitled “Multivascular PCI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.